PARD (Poniard Pharmaceuticals) Debt-to-EBITDA : -0.12 (As of Sep. 2011)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poniard Pharmaceuticals Debt-to-EBITDA?

Poniard Pharmaceuticals PARD Debt-to-EBITDA is -0.12 as of Sep. 2011.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Poniard Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2011 was $0.00 Mil. Poniard Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2011 was $1.64 Mil. Poniard Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2011 was $-13.75 Mil. Poniard Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2011 was -0.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Poniard Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

PARD's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.14
* Ranked among companies with meaningful Debt-to-EBITDA only.

Poniard Pharmaceuticals  (OTCPK:PARD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Poniard Pharmaceuticals Debt-to-EBITDA Related Terms

Poniard Pharmaceuticals Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Debt-to-EBITDA Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.82 -0.32 -0.53 -0.52 -0.06

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -0.09 -0.14 -0.12 -0.12

PARD vs OBMP, NSPX, ATRX: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Debt-to-EBITDA falls into.


Poniard Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Poniard Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2010 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 1.574) / -25.019
=-0.06

Poniard Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2011 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 1.64) / -13.748
=-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2011) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.12 mean?
Poniard Pharmaceuticals (PARD) has a Debt-to-EBITDA of -0.12 as of Sep. 2011. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Poniard Pharmaceuticals.
Is Poniard Pharmaceuticals' Debt-to-EBITDA too high?
Poniard Pharmaceuticals' current Debt-to-EBITDA is -0.12.
How does Poniard Pharmaceuticals' Debt-to-EBITDA compare to OBMP and NSPX?
Poniard Pharmaceuticals' Debt-to-EBITDA of -0.12 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Poniard Pharmaceuticals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poniard Pharmaceuticals's current Debt-to-EBITDA is -0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Debt-to-EBITDA of -0.12. The current Debt-to-EBITDA is -0.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Debt-to-EBITDA is -0.12 as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.